VKTX 51.53 (+0.04%)
US92686J1060BiotechnologyBiotechnology

Viking Therapeutics (VKTX) Stock Highlights

51.53 | +0.04%
2024-11-21 01:12:05
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The companys clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Statistics

Range Today
50.4 53.04
Volume Today 3.48M
Range 1 Year
11.21 99.41
Volume 1 Year 1.1B
Range 3 Year
2.02 99.41
Volume 3 Year 2.16B
Range 10 Year
0.88 99.41
Volume 10 Year 4.16B

Highlights

Market Capitalization 7.63B (mid)
Floating Shares 105.46M
Current Price 51.53
Price To Earnings -73.14
Price To Book 8.37
Earnings Per Share -0.94
Payout Ratio 0%

Performance

Latest +0.04%
1 Month -21.04%
3 Months -19.36%
6 Months -22.92%
1 Year +354.01%
3 Years +785.4%
5 Years +605.89%
10 Years +544.13%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.